Photobiomodulation Equipment and Training - THOR Photomedicine

Select Region

Information contained on this page may not be appropriate for your region, please select your region from below. To navigate back to this region selector, please click "Region" in the footer.
Do More With A THOR
Lots of happy THOR customer testimonials
NovoTHOR Whole Body Light Pod

Photobiomodulation for Wound Healing

Clinical Research

Photobiomodulation (PBM Therapy) previously known as Low Level Laser Therapy (LLLT) is the application of red light and near infrared radiation to stimulate healing and relieve pain. There is usually no sensation or side effects. The new accepted term for this effect is Photobiomodulation.

Dr Endre Mester, the father of laser therapy
Dr Endre Mester
The father of laser therapy


In 1967 a few years after the first working laser was invented, Endre Mester in Semmelweis University Budapest, Hungary wanted to find out if laser might cause cancer. He took some mice, shaved the hair off their backs, divided them into two groups and gave a laser treatment with a low powered ruby laser to one group. They did not get cancer and to his surprise the hair on the treated group grew back more quickly than the untreated group. That was how "laser biostimulation" was discovered.

Effect of laser on hair Growth of mice (in Hungarian). Mester, E. Szende, B. and Tota, J.G. (1967). Kiserl Orvostud 19. 628-631

13 week old pressure sore, treatment twice a week for 10 mins with a THOR LED cluster probe

PBM Wound Healing 1 PBM Wound Healing 2 PBM Wound Healing 3
Before first
laser treatment
Week 3 after
first laser treatment
Week 6 after
first laser treatment


Adltya K. Gupta, MD, FRCP(C)), Natalia Filonenko, PhD, Norman Salansky, PhD, flms, Daniel N. Sadder, MD, FRCP(C)

BACKGROUND. Venous ulcers are estimated to be present in 0.2 to 0.4% of the population. Although new therapies have significant promise, nonhealing ulcers still represent a significant problem. Objective. To evaluate the efficacy of low energy photon therapy (LEPT) in the treatment of venous leg ulcers.

METHODS. A placebo-controlled, double-blind study using low energy photon therapy was performed in nine patients with 12 venous ulcers. Treatment was given three times a week for 10 weeks, using two monochromatic optical sources. One source provided a wavelength (A) of 660 nm (red) while the second source delivered a wavelength of 880 nm (infrared). Two optical probes were used, one consisted of an array of 22 monochromatic sources, operating at a wavelength of 660 nm and covering an area 6 x 10 cm2. The second probe had seven infrared sources, operating at a wavelength of 880 nm and covering an area of 4 cm2 The above configuration of optical probes was selected to cover the majority of the ulcer area being treated. The patients who were randomized to placebo treatment received sham therapy from an identical-appearing light source from the same delivery system.

RESULTS. Nine patients with 12 venous ulcers were randomized to receive LEPT or placebo therapy. At the conclusion of the study, the percentage of the initial ulcer area remaining unhealed in the LEPT and placebo groups was 24.4% and 84.7%, respectively (P = 0.0008). The decrease in ulcer area (compared to baseline) observed in the LEPT and placebo groups was 193.0 mm2 and 14.7 mm2, respectively (P = 0.0002). One patient dropped out of the study, complaining of lack of treatment efficacy; he was found to be randomized to the placebo group. There were no adverse effects.

CONCLUSION. In this placebo-controlled, double-blind study LEPT was an effective modality for the treatment of venous leg ulcers. © 1998 by the American Society for Dermatologic Surgery, Inc. Dermatol Surg 1998;24:1383-1386.

From the Division of Dermatology, Department of Medicine, University of Toronto; International Medical Instruments Inc.; and Selye-Toffler University, Toronto, Ontario, Canada.

© 1998 by the American Society for Dermatologic Surgery, Inc. • Published by Elsevier Science Inc. 1076-0512/98/$19.00 • PII S1076-0512(98)00168-X


Schubert V.

Karolinska Institutet, Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research, Huddinge University Hospital, Stockholm, Sweden.

BACKGROUND: The effects of infrared and red pulsed monochromatic light, with varied pulsations and wavelengths, on the healing of pressure ulcers were evaluated in this prospective, randomized, controlled study. METHODS: Elderly patients (≥ 65 years) with Stage 2 or 3 skin ulcers were enrolled and assigned to one of two groups. Both groups were given the same standard ulcer therapy. One group was also given phototherapy with pulsed monochromatic infrared (956 nm) and red (637 nm) light. Treatments lasted 9 min each time using a regimen with pulse repetition frequency varied between 15.6 Hz and 8.58 kHz. Patients were followed for 10 weeks or until the ulcer was healed, whichever occurred first. The ulcer surface area was traced weekly. RESULTS: Patients treated with pulsed monochromatic light had a 49% higher ulcer healing rate, and a shorter time to 50% and to 90% ulcer closure compared with controls. Their mean ulcer area was reduced to 10% after 5 weeks compared with 9 weeks for the controls.

CONCLUSION: The results are encouraging as pulsed monochromatic light increased healing rate and shortened healing time. This will positively affect the quality of life in elderly patients with pressure ulcers.

Photodermatol Photoimmunol Photomed. 2001 Feb;17(1):32-8.


M.E. Sugrue, FRCSI, J. Carolan, BSc, E.J. Leen, MB, T.M. Feeley, FRCSI, D.J. Moore, FRCSI, G.D. Shanik, FRCSI, Dublin Ireland.

Management of intractable venous ulceration remains an unrewarding task, which is increasingly delegated to the realm of the vascular surgeon. The purpose of this pilot study was to assess the ulcer-healing effects of the newest form of biostimulation—the low power laser. Twelve patients with chronic venous ulcers unresponsive to conservative measures were treated with infrared laser irradiation for twelve weeks. Two ulcers healed completely and there was a 27% (p<0.01) reduction in size of the remaining ulcers. Treatment resulted in a 44% (p<0.01) increase in ulcer floor area occupied by healthy granulation tissue. The most dramatic effect of laser treatment was the reduction in ulcer pain, from 7.5 to 3.5 (linear analogue scale) (p<0.001). Laser irradiation had no effect on TcPO2, number of skin capillaries of pericapillary fibrin deposition in the lipodermatosclerotic area around the ulcer. The results of this pilot study are encouraging and a carefully controlled randomized study is indicated to compare low power laser irradiation to conventional treatment in the management of venous ulcers.

(Ann Vasc Surg 1990;4:179-181).


Verdote-Robertson-R, Munchua-M-M, Reddon-J-R.

The effect of low intensity laser therapy on wound healing in a largely psychogeriatric population was assessed over a period of 6 years (1991-1996). In total, 84 psychiatric patients were referred for the treatment of open wounds of varying severity and etiology. The wound status, nutritional status, walking status, and psychiatric condition of each patient were assessed prior to the administration of laser therapy treatment. Traditional wound care management was also used in addition to laser therapy. According to laser therapy treatment protocol for open wounds, a single diode laser probe was used for biostimulation of the wound bed and the wound periphery. Pre- and post-treatment measurements of wound size were obtained periodically for a total of 188 open wounds. 84% of these wounds completely healed, 11.2% partially healed, 2.1% did not change, and 2.7% got worse. The number of treatments for the 158 completely-healed wounds ranged from 3 to 133 (mean 18.5) and the treatment period ranged from 5 to 383 days (mean 47.7). Wound healing was found to be related to nutritional status but neither walking status nor wound size. Results indicate that LILT is effective in the treatment of open wounds when it is used as a component of a total wound management program.

Physical and Occupational Therapy in Geriatrics. 2000, 18/2 (1-19)

Physiological Changes


Our customers include: Harvard Medical School, Massachusetts General Hospital, British Army, RAF, Royal Navy, Team GB, Manchester United, MIT, Harvard School of Public Health, Cedars Sinai, City of Hope, USUHS
THOR Customers

THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.

The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.

The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.

Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.

Positive systematic reviews published by:

The British Medical Journal (BMJ), The Lancet, the International Association for the Study of Pain (IASP), the World Health Organisation (WHO), the Multinational Association for Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO)

Appropriate regulatory clearance or approvals include:

Quality certificates